Janus Kinase (JAK) Inhibitors - Competitive Landscape, Technology and Pipeline Analysis, 2017

    Janus Kinase (JAK) Inhibitors - Competitive Landscape, Technology and Pipeline  Analysis, 2017
    Date: 01 Nov, 2017
    Type: Pharmaceutical
    Pages: 323
    Geography: Global
    Code: DISR0006
    Delivery Timeline: 24 Hours

    DelveInsight's, "Janus Kinase (JAK) Inhibitors- Competitive Landscape, Pipeline and Market Analysis, 2017", report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Janus Kinase (JAK) Inhibitors. This report provides information on the therapeutic development based on Janus Kinase (JAK) Inhibitors mechanism of action dealing with around 35+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs. DelveInsight's Report also assesses the Janus Kinase (JAK) Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 25+ active companies involved in the therapeutic development of the products.
    • The report provides competitive pipeline landscape of Janus Kinase (JAK) Inhibitors
    • The report provides the marketed drugs information including its sales, development activities and details of patent expiry
    • The report provides the insight of current and future market for Janus Kinase (JAK) Inhibitors
    • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
    • Coverage of the Janus Kinase (JAK) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
    • The report reviews key players involved in the therapeutics development for Janus Kinase (JAK) Inhibitors and also provide company profiling
    • The report also gives the information of dormant pipeline projects
    • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
    • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
    Reasons to Buy
    • Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
    • Complete MOA intelligence and complete understanding over therapeutics development for Janus Kinase (JAK) Inhibitors
    • Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
    • Devise corrective measures for pipeline projects by understanding Janus Kinase (JAK) Inhibitors pipeline depth and focus of Indication therapeutics
    • Developing strategic initiatives to support your drug development activities.
    • Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
    • Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
    • Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

    Executive Summary
    Executive Summary Snapshot
    Janus kinase Inhibitors (JAK Inhibitors) Overview
    Structure and Mechanism
    Janus Kinase Inhibitors
    Types of JAK Inhibitors
    Cytokines associated with Janus kinases and result of their mutations
    JAK Inhibitors Market Analysis
    Collaborations and Deals
    Acquisition Deals
    Designations Analysis
    Companies Involved in JAK Inhibitor Development
    Therapeutic Targets by Company and Indication
    Market Drivers and Barriers
    Marketed Products
    Therapeutics under Development by Companies
    Late Stage Products (Filed &Phase III)
    Comparative Analysis
    Mid Stage Products (Phase II)
    Comparative Analysis
    Early Stage Products (Phase Iand IND)
    Comparative Analysis
    Discovery and Pre-clinical stage Products
    Comparative Analysis
    Therapeutic Assessment
    Assessment by Monotherapy Products
    Assessment by Route of Administration
    Assessment by Stage and Route of Administration
    Assessment by Molecule Type
    Assessment by Stage and Molecule Type
    Dormant Products
    Companies involved in Therapeutics Development
    Upcoming Conferences
    SWOT Analysis for JAK Inhibitors
    Consulting Services
    About DelveInsight
    Contact Us

    Table 1:Collaboration and Deal Values for JAK Inhibitors, 2017
    Table 2:Acquisition deals for the development of JAK Inhibitors , 2017
    Table 3: Grants, 2017
    Table 4:Number of Products Under Development for Janus Kinase (JAK) Inhibitors, 2017
    Table 5: Number of Products under Development by Companies, 2017
    Table 6: Late Stage Products (Filed &Phase III),2017
    Table 7: Mid Stage Products (Phase II),2017
    Table 8: Early Stage Products (Phase Iand IND), 2017
    Table 9: Discovery and Pre-clinical stage Products, 2017
    Table 10: Assessment by Monotherapy Products, 2017
    Table 11: Assessment by Route Of Administration, 2017
    Table 12:Assessment by Stage and Route Of Administration, 2017
    Table 13: Assessment by Molecule Type, 2017
    Table 14: Assessment by Stage and Molecule Type, 2017
    Table 15: Dormant Products, 2017
    Table 16: Discontinued Products, 2017
    Table 17: AbbVie, Overview, 2017
    Table 18: Aclaris Therapeutics, Inc., Overview, 2017
    Table 19: Advinus Therapeutics, Overview, 2017
    Table 20: Amgen Inc., Overview, 2017
    Table 21: Aptose Biosciences, Overview, 2017
    Table 22: Arrien Pharmaceuticals, Overview, 2017
    Table 23: Asana BioSciences, Overview, 2017
    Table 24: Astellas Pharma Inc., Overview, 2017
    Table 25: Astrazeneca, Overview, 2017
    Table 26:Bristol-Myers Squibb, Overview, 2017
    Table 27: CleveXel Pharma, Overview, 2017
    Table 28: Cloud pharmaceuticals, Overview, 2017
    Table 29: Concert Pharmaceuticals, Overview, 2017
    Table 30: CTI BioPharma, Overview, 2017
    Table 31: Cytopia Research, Overview, 2017
    Table 32: Eli Lilly and Company, Overview, 2017
    Table 33: Galapagos NV, Overview, 2017
    Table 34: Gilead Sciences, Overview, 2017
    Table 35: Hoffmann-La Roche, Overview, 2017
    Table 36: Incyte Corporation, Overview, 2017
    Table 37: Japan Tobacco Company, Overview, 2017
    Table 38: Nimbus Therapeutics, Overview, 2017
    Table 39: Pfizer Inc., Overview, 2017
    Table 40: Portola Pharmaceuticals, Overview, 2017
    Table 41: Sareum Limited, Overview, 2017
    Table 42: Theravance Biopharma, Overview, 2017
    Table 43: Tragara Pharmaceuticals, Overview, 2017
    Table 44: Vectura Group, Overview, 2017

    Figure 1: Structure of Janus Kinase
    Figure 2: Illustrated mechanism of Janus Kinase
    Figure 3: Collaboration and Deals for JAK Inhibitors, 2017
    Figure 4: Number of Companies under acquisition for JAK Inhibitors, 2017
    Figure 5: Designation Analysis for JAK Inhibitors, 2017
    Figure 6: Grants, 2017
    Figure 7: Number of Products under Development for JAK Inhibitor, 2017
    Figure 8: Number of Products under Development for Janus Kinase(JAK) Inhibitors, 2017
    Figure 9: Late Stage Products (Filed &Phase III),2017
    Figure 10: Mid Stage Products (Phase II),2017
    Figure 11:Early Stage Products (Phase Iand IND ), 2017
    Figure 12: Discovery and Pre-clinical stage Products, 2017
    Figure 13: Number of Products under Development forJAK Inhibitors,2017
    Figure 14: Assessment by Route of Administration, 2017
    Figure 15: Assessment by Stage and Route of Administration,2017
    Figure 16: Assessment by Molecule Type,2017
    Figure 17: Assessment by Stage and Molecule Type,2017
    Figure 18: Dormant Products, 2017
    Figure 19:Discontinued Products, 2017

    Therapy Pipeline scenario

    Current Prominent Research Areas and Key Players

    Collaborations details and Deal values

    Technologies and Targeted antigens

    Pipeline product profiles, Technologies

    Licensing opportunities

    Market Drivers and Barriers

    SWOT Analysis
    • Single User License
    • Site License
    • Global License

    Why Us?

    Diligent Market mission is to provide "insight across the value chain" to help organizations make important business decisions through the use and analysis of actionable market intelligence. It is our mission to provide the most effective results and services coupled with acute client care to create a long-lasting relationship with our clients.